AMLX insider trading
HealthcareAmylyx Pharmaceuticals, Inc.: insider trade history from SEC Form 4 filings.
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Company website: amylyx.com
AMLX insider activity at a glance
FilingIQ tracks 240 insider transactions for AMLX in filings since Jan 10, 2022. The most recent transaction is dated Sep 10, 2026.
Across the full history, 17 open-market purchases
and 136 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on AMLX insider trades is 50.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest AMLX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for AMLX?
- FilingIQ tracks 240 Form 4 insider transactions for AMLX (Amylyx Pharmaceuticals, Inc.), covering filings from Jan 10, 2022 onwards. 19 of those are dated within the last 90 days.
- Are AMLX insiders net buyers or net sellers?
- Across the full Form 4 history for AMLX, 17 transactions (7%) were open-market purchases and 136 (57%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does AMLX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is AMLX in?
- Amylyx Pharmaceuticals, Inc. (AMLX) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $1.57B.
Methodology & sources
Every AMLX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.